Treatment of malignant skin tumours with oral administration of BCG in enteric-coated capsules

Dev Biol Stand. 1986;58 ( Pt A):465-74.


27 patients of stage Ib and 2 of malignant melanoma selected randomly were treated with the oral administration of BCG in enteric coated capsules in addition to the chemotherapy after the surgical treatment, while another 27 patients of the same stage of malignant melanoma with about the same background were treated with the same chemotherapy without BCG administration after the surgical treatment at the same period. The survival rate and the disease free time were observed in the patients of both groups with the results that the BCG group showed a significantly higher survival rate and a slightly higher disease free time than the control group. As an immunoparameter, the PPD reactions showed a higher conversion rate and increasing reaction size of the positive reactors in BCG group. Increasing the number of patients and observation period, the study will be continued in future.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Administration, Oral
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • BCG Vaccine / administration & dosage
  • BCG Vaccine / adverse effects
  • BCG Vaccine / therapeutic use*
  • Combined Modality Therapy
  • Humans
  • Neoplasm Staging
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy*
  • Tablets, Enteric-Coated


  • BCG Vaccine
  • Tablets, Enteric-Coated